#21-1344 Summer Street
Halifax, NS B3H 0A8
Canada
902-442-4655
https://www.appilitherapeutics.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 8
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Donald D. Cilla Jr., M.B.A., Pharmd | CEO, President & Director | 568.27k | N/A | N/A |
Mr. Kenneth G. Howling | Chief Financial Officer | 522.62k | N/A | N/A |
Dr. Gary S. Nabors Ph.D. | Chief Development Officer | N/A | N/A | N/A |
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.
Appili Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.